MannKind Corporation (MNKD)
| Market Cap | 803.49M |
| Revenue (ttm) | 62.69M |
| Net Income (ttm) | -45.09M |
| Shares Out | 229.67M |
| EPS (ttm) | -0.21 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 19 |
| Last Price | $3.21 |
| Previous Close | $3.14 |
| Change ($) | 0.07 |
| Change (%) | 2.23% |
| Day's Open | 3.18 |
| Day's Range | 3.12 - 3.28 |
| Day's Volume | 3,454,593 |
| 52-Week Range | 0.84 - 4.04 |
MannKind Corporation (MNKD) CEO Michael Castagna Presents at H.C. Wainwright Bioconnect 2021 Brokers Conference (Transcript)
WESTLAKE VILLAGE, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for ...
MannKind (MNKD) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
WESTLAKE VILLAGE, Calif. and NEW PROVIDENCE, N.J., Dec. 17, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) and Vertice Pharma today announced that they have entered into a co-pro...
Kent Kresa, former Chairman, will continue to serve as a Director Kent Kresa, former Chairman, will continue to serve as a Director
Lead investigational product (inhaled clofazimine) designated by the FDA as an orphan drug and qualified infectious disease product Lead investigational product (inhaled clofazimine) designate...
WESTLAKE VILLAGE, Calif., Nov. 19, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced that it has achieved the final development milestone under its licensing and coll...
NEW YORK, Nov. 10, 2020 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiducia...
MannKind Corporation (MNKD) CEO Michael Castagna on Q3 2020 Results - Earnings Call Transcript
MannKind (MNKD) delivered earnings and revenue surprises of -25.00% and -2.48%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Conference Call to Begin Today at 5:00 PM ET
MannKind Corporation is a biopharma company focused on developing and commercializing inhaled therapeutics for endocrinology and lung diseases. Mannkind has one FDA-approved inhalable insulin ...
WESTLAKE VILLAGE, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2020 third quarter financial results and its management will host a conference c...
MannKind (MNKD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MannKind Corporation (MNKD) CEO Michael Castagna Presents at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Transcript)
MannKind Corporation (MNKD) CEO Michael Castagna Presents at Cantor 2020 Global Virtual Healthcare Conference (Transcript)
MannKind Corporation's (MNKD) CEO Michael Castagna at H.C. Wainwright 22nd Annual Global Investment Conference (Transcript)
MannKind Corporation's (MNKD) CEO Michael Castagna at H.C. Wainwright 2second Annual Global Investment Conference (Transcript)
WESTLAKE VILLAGE, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products f...
WESTLAKE VILLAGE, Calif., Aug. 31, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) today announced that Kevin Kaiserman, MD, has joined the company as Vice President, Medical Af...
MannKind (MNKD) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
WESTLAKE VILLAGE, Calif., Aug. 07, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products fo...
MannKind Corporation's (MNKD) CEO Michael Castagna on Q2 2020 Results - Earnings Call Transcript
MannKind (MNKD) delivered earnings and revenue surprises of 0.00% and -0.52%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Conference Call to Begin Today at 5:00 PM ET Conference Call to Begin Today at 5:00 PM ET
MannKind Corporation to Hold 2020 Second Quarter Financial Results Conference Call on August 5, 2020
WESTLAKE VILLAGE, Calif., July 29, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2020 second quarter financial results and its management will host a conferenc...
MannKind (MNKD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Today has brought good news. Consumer confidence is better than expected and unemployment has decreased.
We will have to wait to see if the wind is truly changing to the bears, or if the bulls can come back throughout the day – either way, our deep learning algorithms paired with Artificial Intel...
MannKind Corporation (MNKD) CEO Michael Castagna Presents at Lytham Partners Virtual Investor Growth Conference (Transcript)
Before you consider going all in on MNKD stock, consider that the company is itself going all in on one product, and that comes with risks. The post MannKind Is Crushing It, but Beware or You’...
MannKind (MNKD) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Investors need to pay close attention to MannKind (MNKD) stock based on the movements in the options market lately.
WESTLAKE VILLAGE, Calif., June 17, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) announced today that it will be featured in a virtual presentation and fireside chat at the Jun...
Momentum is still in swing from the biotech's recent presentations.
Investors liked the biotech's presentations at a major diabetes conference.
WESTLAKE VILLAGE, Calif., June 15, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced that new data from clinical studies of Afrezza® (insulin human) Inhalation Powder wa...
WESTLAKE VILLAGE, Calif., June 13, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced that data from a new clinical study of Afrezza® (insulin human) Inhalation Powder wi...
If there’s one thing that's been made more clear, it’s that the stock market and economy are not reflections of each other. An overbought stock market will eventually turn to the downside, and...
As tensions continue to rise both domestically and internationally, taking a short position isn't a bad idea. Our deep learning algorithms have identified these 5 companies as the top stocks t...
MannKind Corporation's (MNKD) CEO Michael Castagna on Q1 2020 Results - Earnings Call Transcript
MannKind (MNKD) delivered earnings and revenue surprises of 50.00% and 7.16%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
MannKind (MNKD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
WESTLAKE VILLAGE, Calif., March 24, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced that Jennifer Grancio has been appointed to its Board of Directors, effective ...
An overall market rebound and some company-specific news are lighting a fire beneath these stocks.
MannKind Corporation (MNKD) CEO Michael Castagna on Q4 2019 Results - Earnings Call Transcript
The biotech met or exceeded Wall Street expectations in Q4. But its top and bottom lines are headed in the wrong direction.
Each year, MoneyShow asks the nation’s leading financial newsletter advisors for their favorite stocks for the coming year. Here are seven favorites from the pharmaceutical and biotechnology s...
The short interest data are out for the most recent settlement date, December 13. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big p...
Publication in DIABETICMedicine Now Available Online Publication in DIABETICMedicine Now Available Online
About MNKD
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for diabetes and pulmonary arterial hypertension patients in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. The company has a license and collaboration agreement with United Therapeutics Corporation for the development and commercialization of a dry powder formulation of treprostinil used for the treatment of pulmonary arterial hypertension. MannKi... [Read more...]
| Industry Biotechnology | IPO Date Jul 28, 2004 |
| CEO Michael Castagna | Employees 232 |
| Stock Exchange NASDAQ | Ticker Symbol MNKD |
Financial Performance
In 2019, MNKD's revenue was $63.04 million, an increase of 126.28% compared to the previous year's $27.86 million. Losses were -$51.90 million, -40.32% less than in 2018.
Analyst Forecasts
According to 5 analysts, the average rating for MNKD stock is "Strong Buy." The 12-month stock price forecast is 3.30, which is an increase of 2.80% from the latest price.